Why the study?
Does Allisartan Isoproxil 240mg once daily reduce blood pressure in essential hypertensive patients at low-medium risk?
Population
275 essential hypertensive patients at low-medium risk across 8 sites in China.
Comparison
Allisartan Isoproxil 240mg once-daily for 8 weeks. vs Placebo once-daily for 8 weeks.
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
8 weeks (primary), up to 64 weeks (extension)
Authors
Loading...
Supports Allisartan Isoproxil 240 mg daily for low-medium risk essential hypertension; confirms RCT efficacy versus placebo.
Does Allisartan Isoproxil 240mg once daily reduce blood pressure in essential hypertensive patients at low-medium risk?
Allisartan Isoproxil 240mg once daily effectively and safely reduces blood pressure in patients with low-to-medium risk essential hypertension.
Li et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: